Further studies of the impact of HLA‐DRB1 ST‐MM, isolated or in combination with HLA‐DQB1 AL MM, on other kidney transplant outcomes, including de novo DSA and long‐term graft survival, are urgently needed because matching for HLA‐DRB1 ST represents a very promising tool for assessing transplant immunologic risk and for inclusion in DD kidney allocation algorithms. Here, HLA-DRB1 is linked to Miyoshi myopathy.